Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter ≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surfactant (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.

Abstract: A class of water insoluble iodophors comprising complexes of iodine with various nylons such as nylon-4,6, nylon-6, nylon-6,6 or other polyamides is disclosed. These nylons complexed with iodine can be made in various forms such as powders, pellets, molded objects, granules, films, monofilaments, and either non-woven or woven fabrics. These nylon based iodophors and other water insoluble iodophors herein disclosed can find product applications in the fields of air treatment, water treatment, public hygiene and medicine.

Abstract: A cosmetic sea salt scrub is provided which includes sodium sesquicarbonate and an oil. Sodium sesquicarbonate ordinarily is the major salt present and amounts of this salt relative to the oil may range from about 20:1 to about 5:1 by weight. Mineral oil is particularly preferred as the oil phase. Salt scrubs according to this invention are relatively uniform in composition, easily dispensed from a jar and spread uniformly on the skin.

Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.

Abstract: The present invention describes the use of finely divided dye-containing polymers PD in the form of an aqueous polymer dispersion or a polymer powder obtainable therefrom, the polymer matrix of which comprises at least one organic dye D in homogeneously dispersed form, as color-imparting constituent in cosmetic compositions. The present invention also describes cosmetic compositions which comprise a color-containing polymer in an amount of from 0.1 to 50% by weight, based on the total weight of the cosmetic composition, and additives customary for cosmetic compositions.

Abstract: Microspheres, having a size lower than 1&mgr; and comprising a biocompatible polysaccharidic polymer, are prepared with a process comprising the precipitation of polymer induced by means of a supercritical antisolvent (SAS). These microspheres are used as vehicling agents or carriers in the preparation of pharmaceutical compositions administrable by oral, nasal, pulmonary, vaginal or rectal route. These microspheres can also be advantageously used as vehicling agent or carriers in the preparation of pharmaceutical compositions for the treatment of human diseases associated with genic defects, for the preparation of diagnostics and in the agro-alimentary industry.

Abstract: A dosage form containing cetirizine as an immediate release component and pseudoephedrine or a pharmaceutically acceptable salt thereof as a controlled release component. A portion of the pseudoephedrine can also be incorporated as an immediate release component. The dosage form is free of alcohols having a molecular weight lower than 100 and reactive derivatives thereof.

Abstract: The invention relates to compositions such as body and hair cleansing products, in particular shampoos, comprising one or more antifungals inhibiting fungal ergosterol biosynthesis as a first active ingredient and 10′-undecen-3-oyl-aminopropyl trimethyl-ammonium methylsulfate as a second active ingredient.

Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Abstract: Method and apparatus for preparing microparticles using liquid-liquid extraction. A first phase and a second phase are combined to form an emulsion. A portion of the second phase is separated from the emulsion (solvent rich), and the solvent is extracted from the separated second phase, which is then returned (solvent poor) to the emulsion. This process of separation of a solvent rich phase, extraction of solvent, and return of a solvent poor phase, is carried out until a selected level of solvent in the emulsion is achieved. Alternatively, the separated solvent rich phase is not returned to the emulsion, but replaced with another solution, such as an aqueous solution, that is free from solvent. The solvent is preferably extracted into an extraction liquid that functions as a “solvent sink” for the solvent.

Abstract: A personal care composition having synergistic rheological properties and aesthetic and functional gel at low solids blends comprising a blend of (a) a terpolymer of polyvinylpyrrolidone, acrylic acid and laurylmethacrylate; and (b) a copolymer of acrylates and steareth-20 methacrylate.

Abstract: A fluoride-releasing dental amalgam composition for a tooth restoration comprising a dental amalgam alloy material and an fluoride-containing, the glass particulate powder component of a fluoride-leachable acid-etchable glass ionomer cement. The invention further provides a method for using the composition to prevent or reduce secondary caries in an existing tooth restoration, which is classified as a dental amalgam in nature.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: A biodegradable vehicle and filler (referred to in this invention as biodegradable vehicle), which can be mixed with one or more biologically active substances (BAS), or can be used as a biodegradable filler to fill in cavities or body tissues in animals, birds and humans. The consistency and rheology, hydrophilicity and hydrophobicity, and in vivo degradation rates of the biodegradable vehicle is controlled by modulating the molecular weight of polymers and copolymers, concentration of plasticizers, ratios of two or more plasticizer in the blends, types of polymers and copolymers, copolymer ratios, and ratios of blends of polymers with different molecular weights or different copolymers. The biodegradable vehicle is mixed with one or more BAS (which is separately stored away from the biodegradable vehicle in an appropriate container) just prior to use.

Abstract: The present invention is directed to low VOC, non-aerosol hair cosmetic compositions, which contain nonionically modified starches. The starch may be additionally hydrolyzed, particularly enzymatically hydrolyzed. Further, the starch may be modified using ionic substituents. Use of such starches is novel and advantageous in that they provide a clear solution with a low viscosity, and good pump spray characteristics. Further, the resultant composition provides a clear film which is not tacky, good stiffness, and improved humidity resistance.

Abstract: A device, methods and pharmaceutical compositions are disclosed for transnasal or transocular drug delivery to the central nervous system using a combination of electrotransport or phonophoresis with chemical permeation enhancers.

Abstract: The subject invention is a carrier or product formed of a matrix having starch, sugar, fat, polyhydric alcohol and water in suitable ratios such that there exists a water activity of 0.6-0.75. The water activity of the product matrix may be adjusted up or down so that the availability of water in the finished product is not detrimental to the included active ingredient, be it pharmaceutical, nutraceutical, or a vitamin mineral complex.

Abstract: The present invention relates to a novel hydrocolloid adhesive mass useful for medical purposes, characterized in that said hydrocolloid adhesive mass comprises: a) 0.2 to 5 parts by weight of an ethoxylated sorbitan fatty acid ester; b) 20 to 50 parts by weight of a hydrocolloid; c) 32 to 120 to parts by weight of an adhesive matrix made up of one or more polymers selected from poly(styrene/olefin/styrene) block copolymers, low-molecular polyisobutylenes and high-molecular polyisobutylenes, and one or more compounds selected from sticky resins, or tackifying resins, plasticizers, polybutenes, antioxidants, ethylene/vinyl acetate copolymers, butyl rubbers and ethylene/propylene block copolymers; and d) 0 to 15 parts by weight of an acrylate copolymer with a glass transition temperature below −20° C.

Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Abstract: Process for the preparation of a composition in the form of an inverted latex, comprising an oil phase, an aqueous phase, at least one emulsifier of water-in-oil (W/O) type, at least one emulsifier of oil-in-water (O/W) type, from 20% to 70% by weight, and preferably from 25% to 45% by weight, of a branched or crosslinked anionic polyelectrolyte based on a monomer possessing a strongly acidic function, characterized in that a) an aqueous solution containing the monomers and the optional additives and adjusted beforehand to a pH below 4 is emulsified in an oil phase in the presence of one or more emulsifiers of water-in-oil type, b) the polymerization reaction is initiated by introducing a free-radical initiator into the emulsion formed in a), after which the reaction is left to proceed, c) when the polymerization reaction is complete, one or more emulsifiers of oil-in-water type are introduced at a temperature below 50° C.